MedTrace Logo

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

NCT04104672 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2026-05-07

No results posted yet for this study

Summary

This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.

Conditions

  • Advanced Pancreatic Cancer

Interventions

DRUG

AB680

AB680 is a Cluster of Differentiation (CD)73 Inhibitor.

DRUG

Zimberelimab

Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.

DRUG

Nab-paclitaxel

Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

DRUG

Gemcitabine

Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

Sponsors & Collaborators

  • Arcus Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Arcus Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-06
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04104672 on ClinicalTrials.gov